Ablynx CEO: fundraising lets us take on more risk and responsibility
This article was originally published in Scrip
Executive Summary
With the €50 million Ablynx has just raised, the Belgian antibody firm has extended its ability to take on more risks in return for greater potential rewards, and to progress its internal programmes, CEO Dr Edwin Moses told Scrip, the day after closing the secondary public offering. "Even without it we had well over two years in funding available," he noted, "but this gives us flexibility and choice."